Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Biology of Waldenström macroglobulinemia

Véronique Leblond • 1 Sep 2020
EBMT 2020
Rare Diseases Waldenström’s Macroglobulinemia Antibodies Bendamustine Ibrutinib Rituximab

Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, discusses common genetic variations seen in patients with Waldenström macroglobulinemia and touches on how a greater understanding of the disease, can support treatment strategies, including treatment with ibrutinib, a tyrosine kinase inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Véronique Leblond

3:06
CLL: the GREEN study
Véronique Leblond • 20 Aug 2020
1:43
Current research in Waldenström’s macroglobulinemia
Véronique Leblond • 20 Aug 2020
1:14
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy
Véronique Leblond • 4 Dec 2015
3:22
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Véronique Leblond • 4 Dec 2015

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals